On March 17, 2021 Minomic reported that positive results from our collaborative research evaluating Minomic’s GPC-1 antibody for the detection of pancreatic cancer (one of the deadliest cancers) in collaboration with BARD1 Life Sciences Ltd EXO-NET exosome capture technology (Press release, Minomic, MAR 17, 2021, View Source [SID1234577225]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Minomic’s GPC-1 antibody specifically binds EXO-NET isolated exosomes from pancreatic cancer but not healthy exosomes demonstrating a feasible approach for pancreatic cancer detection. You can read the ASX release from BARD1 here: View Source

We continue with the roll-out of our MiCheck Prostate test in Australia having piloted patient testing at Macquarie University Hospital Urology Clinic. We are also well progressed with our US roll-out plans.